SCHEMBL4188465

SCHEMBL4188465

COc1ccc(/C=C/C(=O)O)cc1Br

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.73
ALDH1A1 P00352 4/20 0.73
HPGD P15428 3/20 0.73
MAPK1 P28482 2/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
HSD17B10 Q99714 2/20 0.73
ALOX15 P16050 1/20 0.73
CTSL P07711 3/20 0.66
RECQL P46063 1/20 0.66
GAA P10253 1/20 0.66
SNCA P37840 2/20 0.65
PKM P14618 2/20 0.65
CA12 O43570 1/20 0.65
CA1 P00915 1/20 0.65
CA2 P00918 1/20 0.65
CA3 P07451 1/20 0.65
CSNK2A2 P19784 1/20 0.65
CA4 P22748 1/20 0.65
CA6 P23280 1/20 0.65
CA5A P35218 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4188471 1.00 KDM4E (0.73) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL6330141 0.92 KDM4E (0.62) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL30853135 0.87 KDM4E (0.73) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL731054 0.87 KDM4E (0.73) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL731055 0.87 KDM4E (0.73) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL4176326 0.86 RECQL (0.68) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
SCHEMBL4176324 0.86 RECQL (0.68) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
O,O'-Dimethylcaffeic Acid SCHEMBL81318 0.85 KDM4E (1.00) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
O,O'-Dimethylcaffeic Acid SCHEMBL29636389 0.85 KDM4E (1.00) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2
O,O'-Dimethylcaffeic Acid SCHEMBL81317 0.85 KDM4E (1.00) KDM4EALDH1A1HPGDMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117264935-A Phenylalanine ammonia lyase mutant and application thereof 中国科学院成都生物研究所 2023-12-22 CN disclosed
CN-117264935-A Phenylalanine ammonia lyase mutant and application thereof 中国科学院成都生物研究所 2023-12-22 CN disclosed
EP-3615514-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2023-11-22 EP disclosed
CN-110914242-B Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2023-07-25 CN disclosed
US-11603349-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD (AU) 2023-03-14 US disclosed
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD (AU) 2021-08-12 US disclosed
US-11014873-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD. (AU) 2021-05-25 US disclosed
US-10875875-B2 Propionic acid derivatives and methods of use thereof AVIARA PHARMACEUTICALS, INC. (US) 2020-12-29 US disclosed
CN-110914242-A Propionic acid derivatives and methods of use thereof 阿维亚拉药品有限公司 2020-03-24 CN disclosed
EP-3615514-A2 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF Aviara Pharmaceuticals, Inc. (US) 2020-03-04 EP disclosed
EP-0565377-B1 Therapeutic agents for use in the treatment of Parkinson's Disease KYOWA HAKKO KOGYO KK (JP) 1998-01-07 EP disclosed
US-5670498-A ADENOSINE ANTAGONISTS, TREATMENT OF PARKINSON*S DISEASE, ALZHEIMER*S DISEASE, OSTEOPOROSIS, DEPRESSION, ASTHMA KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-09-23 US disclosed
US-5587378-A ADMINISTERING A SUBSTITUTED XANTHINE COMPOUND KYOWA HAKKO KOGYO CO., LTD. (JP) 1996-12-24 US disclosed
EP-0607607-B1 Xanthine derivatives KYOWA HAKKO KOGYO KK (JP) 1996-09-18 EP disclosed
US-5543415-A ADMINISTERING A XANTHINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 1996-08-06 US disclosed
US-5484920-A XANTHINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 1996-01-16 US disclosed
EP-0628311-A1 ANTIDEPRESSANT KYOWA HAKKO KOGYO CO., LTD. (JP) 1994-12-14 EP disclosed
EP-0607607-A1 Xanthine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1994-07-27 EP disclosed
EP-0590919-A1 Therapeutic agents for parkinson's disease KYOWA HAKKO KOGYO CO., LTD. (JP) 1994-04-06 EP disclosed
EP-0565377-A1 Therapeutic agents for use in the treatment of parkinson's disease KYOWA HAKKO KOGYO CO., LTD. (JP) 1993-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603349-B2 Anti-fibrotic compounds TGFB1, SMAD3, TGFB2 KDM4E 4055/4885ALDH1A1 1274/4885HPGD 553/4885
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS TGFB1, SMAD3, TGFB2 KDM4E 4055/4885ALDH1A1 1274/4885HPGD 553/4885
US-11014873-B2 Anti-fibrotic compounds TGFB1, SMAD3, SMAD2 KDM4E 4041/4885ALDH1A1 1184/4885HPGD 522/4885
US-10875875-B2 Propionic acid derivatives and methods of use thereof ITGB3, ITGA1, ITGB5 KDM4E 4039/4885ALDH1A1 263/4885HPGD 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.